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Introduction
Mononuclear phagocytes (ie, monocyte/macrophages) are an 
important part of the bodies’ phagocytic and cell defence sys-
tem and are found in virtually all tissues of the body with large 
numbers in the lymphoid organs, the liver, lungs, and digestive 
tract.1 These cells, influenced by the microenvironment, mount 
specific defence processes. Circulating monocytes will differen-
tiate into tissue macrophages which can be broadly classified in 
2 groups: M1 macrophages, following activation by IFN-γ or 
lipopolysaccharides (LPS) or M2-activated macrophages 
which are further subdivided in M2a (stimulated by interleukin 
4 [IL]-4 or IL-13), M2b (immune complexes in combination 
with IL-1β or LPS), and M2c (IL-10, transforming growth 
factor β or glucocorticoids).2 Activation of macrophages with 
IFN-γ, tumour necrosis factor α and IL-1β significantly 
upregulates the first and rate-limiting enzyme of the kynure-
nine pathway (KP), indoleamine 2,3-dioxygenase (IDO). The 
reasons for why the inflammatory response increases IDO acti-
vation, and subsequent increased flux through the KP, are not 
fully understood. Although previous research has shown a role 
for reducing foetal tissue rejection in allogeneic pregnancy3 and 
certain upstream KP metabolites have antimicrobial activity, 
the reasons for its increase in downstream KP metabolism dur-
ing normal macrophage activation is still unknown.
Previous research using the murine monocyte/macrophage 
cell line RAW264.74 and human astroglial cell line HTB-1385 
suggest a link between the IFN-γ–mediated actions of increased 
free radical synthesis and IDO induction. However, these 
immortalised cell lines are physiologically different from the 
nontransformed cells. Being essentially phenotypically stable, 
these cells do not undergo differentiation (ie, maturation), 
although they can be activated by an appropriate stimulus such 
as IFN-γ. Nontransformed mononuclear phagocytes, however, 
can undergo both differentiation and activation.
After migrating from the bloodstream, monocytes undergo 
irreversible maturation (differentiation) into macrophages and 
tissue-specific cells. The process of proliferation and differentia-
tion is mediated by a variety of specific glycoproteins including 
colony-stimulating factor (CSF-1), granulocyte-macrophage col-
ony-stimulating factor, IL-3, and others.1 Adhesion to the vascu-
lar endothelium is also an early signal for monocyte differentiation 
in vivo.6 In a similar way, adherence to the synthetic substratum of 
a tissue culture dish in vitro has also been shown to facilitate the 
differentiation of isolated monocytes into mature macrophages.7
As the potential for localised DNA damage and subsequent 
poly(ADP-ribose) polymerase (PARP) activation, NAD 
depletion is high in mononuclear phagocytic cells following 
IFN-γ activation.8 The aim of this study was to investigate the 
effect of IFN-γ treatment on intracellular NAD concentration 
and IDO activity in human peripheral blood mononuclear cells 
at different stages of differentiation.
Materials and Methods
Materials
RPMI 1640 was purchased from Life Technologies (Sydney, 
Australia). 3-Aminobenzamide (3ABA), phenazine methosulfate, 
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alcohol dehydrogenase (baker’s yeast), bicine, 3-[4,5-dimethylthi-
azol-2-yl]-2,5-diphenyltetrazolium bromide, catalase (3200 U/
mg solid, bovine liver), tryptophan, and p-dimethylamino-benzal-
dehyde (Ehrlich reagent) were purchased from Sigma-Aldrich 
(Sydney, Australia). Human recombinant IFN-γ was purchased 
from Australian Laboratory Services (Sydney, Australia). Bovine 
calf serum was purchased from Commonwealth Serum 
Laboratories (Sydney, Australia).
Monocyte isolation
Human peripheral blood monocytes were extracted from 
400 mL of whole blood from healthy human immunodeficiency 
virus 1–seronegative volunteers as described by Kazazi et  al.9 
Briefly, blood mononuclear cells were obtained by differential 
centrifugation in Ficoll-Hypaque (Pharmacia-AMRAD, 
Sydney, Australia). Monocytes were separated from other mon-
onuclear cells by counter-current elutriation (Beckman centri-
fuge J-6M/E fitted with a JE-5.0 Elutriation Rotor; Beckman 
Coulter, Sydney, Australia) followed by plastic adherence. Cells 
were plated at a density of 7 × 105 cells/mL of medium which 
consisted of RPMI 1640 supplemented with 10% heat-inacti-
vated foetal bovine serum, 10% heat-inactivated pooled AB+ 
human serum, and 50 μM tryptophan (RF10/10) in a 48-well 
tissue culture plate (Nunc, Sydney, Australia). Cells were then 
placed immediately in a 37°C incubator in a humidified atmos-
phere of 5% CO2.
NAD analysis
The cellular pyridine nucleotide content (NAD+ + NADH) 
was measured by the Thiazolyl blue microcycling assay of 
Bernofsky and Swan adapted to 96-well plate format.10
Quinolinic acid assay
Quinolinic acid (QUIN) was measured by gas chromatogra-
phy-electron capture ion mass spectrometry as described 
previously.11
IDO activity
The IDO activity was determined in the cell homogenate by a 
slight modification of the method of Hara et  al.12 Briefly, 
100 μL of 30% trichloroacetic acid (TCA) was added to 200 μL 
of the culture supernatant, vortexed, and then spun at 
10 000 rpm for 5 minutes. About 125 μL of the supernatant was 
added to 125 μL of Ehrlich reagent (100 mg/5 mL glacial ace-
tic acid) in a microtitre plate well (96-well format). Samples 
were read against a reagent blank with a 492-nm filter in a 
Multiskan MS (Labsystems, Vantaa, Finland) microplate 
reader. The change in kynurenine concentration was obtained 
by subtracting the kynurenine content of fresh uncultured 
media from the value derived from the cultured supernatant.
The kynurenine concentration of samples containing 3ABA, 
which produces spectral interference with the Takikawa method 
(unpublished observations), was obtained using high-perfor-
mance liquid chromatography (HPLC). Briefly, samples for 
HPLC analysis were prepared by precipitating the protein in 
200 μL of sample with 100 μL of 30% TCA. The sample was 
then centrifuged at 15 000 rpm for 5 minutes. About 50 μL of the 
resultant supernatant was injected onto a C18 reverse-phase col-
umn (250 mm × 6 mm). The mobile phase was ammonium ace-
tate buffer (0.1 M, pH 4.65) with 4% acetonitrile. Flow rate was 
0.6 mL/min (GBC LC1150 HPLC pump). Sample was detected 
by UV at 365 nM using a (GBC LC1250 UV/VIS detector).
Experimental procedure
A total of 700 000 freshly elutriated cells were seeded into each 
well of a 24-well culture plate containing 1 mL of culture 
media. IFN-γ (500-600 U/mL) and/or the PARP inhibitor 
3ABA (≥5 mM) was then added to selected wells for 24 or 
48 hours on days 0, 6, and 10 in culture; cells were equilibrated 
for ~30 minutes at 37°C in 5% CO2 before the addition of 
3ABA and/or IFN-γ (Figure 1). At the end of the experimental 
period, the supernatants were aspirated and stored at −80°C 
until analysis for QUIN. Intracellular NAD concentration and 
IDO activity were performed as soon as possible on the soni-
cated whole-cell homogenate, stored at −80°C immediately 
following the experimental period. Remaining cell cultures 
were fed with fresh medium every 3 or 4 days.
Statistical analysis
Results are expressed as the mean ± SEM. Significant differ-
ences between treatment groups was determined using the 
2-tailed t test or, where indicated, analysis of variance with the 
post hoc Tukey-Kramer multiple comparisons test. Differences 
between treatment groups was considered significant if P < .05.
Results
Effect of IFN-γ concentration and exposure time on 
IDO activity in monocytes and macrophages
In this study, we investigated the effect of exposing human 
mononuclear phagocytes at different stages of maturation to 
increasing concentrations of IFN-γ for 24 and 48 hours.
Figure 2 shows that the IFN-γ–mediated increase in IDO 
activity is dependent on both the concentration of IFN-γ, where 
a maximum response is reached at 100 U/mL, and the time in 
culture, which corresponds to the level of cell differentiation.
This same pattern of ‘cell differentiation and exposure time’ 
dependent increase in IDO activity was observed for multiple 
donors (Figure 3), where the IDO activity from cells by day 6 in 
culture exposed to IFN-γ (600 U/mL) for 24 or 48 hours was not 
significantly different from the respective IDO activities measured 
for IFN-γ–treated (24 or 48 hours) day 10 macrophages (Figure 3).
Grant 3
One incongruent result for day 0 monocytes (48-hour 
IFN-γ treatment) from one donor was not included in Figure 
3. These monocytes produced a very high IDO activity 
(57 ± 2 nmol kynurenine/90 min/well, n = 11) compared with 
the mean activity of other donors cells (12 ± 2 nmol kynure-
nine/90 min/well, n = 15), whereas IFN-γ activation of day 10 
macrophages from this same donor produced an IDO activity 
within the normal range (~30 nmol kynurenine/90 min/well) 
(see Figure 2).
Effect of cell maturation on intracellular NAD 
concentration
The intracellular NAD concentration of untreated cells 
increased significantly as cells matured (ie, differentiated) 
Figure 1. Experimental procedure. Human peripheral blood monocytes were maintained in culture for up to 12 days. Cells at different stages of cell 
maturation (differentiation) were treated with IFN-γ and/or 3ABA for 24 or 48 hours before analysis of intracellular NAD and IDO and selected tryptophan 
metabolites in the supernatant. 3ABA indicates 3-aminobenzamide; IDO, indoleamine 2,3-dioxygenase.
Figure 2. Maturation-dependent increase in IDO activity in IFN-γ–activated human monocyte/macrophages from a single donor. Human mononuclear 
phagocytic cells from a single donor cultured for 0 or 10 days were exposed to IFN-γ at a final concentration of 10, 100, or 600 U/mL for either 24 or 
48 hours. IDO activity was determined on the cell homogenate. A dose- (IFN-γ), time-, and maturation-dependent increase in IDO activity was observed. 
*P < .05; **P < .01; ***P < .001 (n = 4-12). Statistics used was the Tukey-Kramer analysis of variance. IDO indicates indoleamine 2,3-dioxygenase.
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from monocytes at day 0 to macrophages by day 10 in culture 
(Figure 4).
Effect of IFN-γ in the absence and presence of 
a PARP inhibitor on monocytes and monocyte-
derived macrophages
After 0, 6, or 10 days in culture, human recombinant IFN-γ 
(600 U/mL) ± the PARP inhibitor (3ABA) was added to 
selected wells for either 24 or 48 hours. Cells were then soni-
cated and assayed for NAD concentration in the cell homoge-
nate. Exposure to IFN-γ for 24 hours decreased intracellular 
NAD in cultures at all stages of differentiation (days 0-6, 
Figure 5A to C). Coadministration of IFN-γ with 3ABA for 
24 hours resulted in a significant increase in cellular NAD lev-
els above treatment with 3ABA alone in both day 6 and day 10 
cultures (Figure 5B and C).
Effect of IFN-γ on QUIN production in monocytes 
and macrophages
Supernatant from selected cultures was analysed for QUIN, 
the final KP intermediate before phosphoribosylation.
Quinolinic acid concentrations were significantly increased 
in the culture supernatant after exposure to IFN-γ for 48 hours 
in both monocytes and macrophages. Quinolinic acid produc-
tion from macrophages was significantly greater than for 
undifferentiated monocytes (Figure 6).
Effect of 3ABA on IDO activity and supernatant 
kynurenine and QUIN concentration in monocytes 
and macrophages
The PARP inhibitor 3ABA was used throughout this study 
as an effective inhibitor of the NAD catabolic enzyme PARP. 
We sought to determine whether 3ABA had any non-specific 
effects on the activity of the KP in either IFN-γ–activated or 
untreated control day 10 macrophages. Figure 7 shows that 
both IDO activity and supernatant kynurenine concentration 
were marginally reduced in IFN-γ–activated macrophages 
treated with 3ABA. Quinolinic acid levels in the supernatant 
were reduced following 3ABA treatment in unactivated mac-
rophages. Although the absolute value for QUIN 
Figure 3. Average, maturation-dependent increase in IDO activity in IFN-γ–activated monocyte/macrophages from multiple donors. Human mononuclear 
phagocytic cells from multiple donors were cultured for 0, 6, or 10 days, then either left untreated (C) or treated with IFN-γ (600 U/mL) for 24 or 48 hours. 
IDO activity was determined on the cell homogenate. ‘A statistically significant time-dependent (24-48 hours) increase in IDO activity was observed for 
day 0 and day 10 cultures’. The response to IFN-γ–induced IDO activity was significantly greater in macrophages (day 10) compared with monocytes (day 
0). *P < .001; **P < .05; ***P < .001 compared with IFN-γ day 0, 48 hours (n = 7-24) separate cultures from 4 different donors. Statistics used was the 
Tukey-Kramer analysis of variance. IDO indicates indoleamine 2,3-dioxygenase.
Figure 4. Intracellular NAD concentrations increase in unstimulated 
human monocyte/macrophages with the degree of differentiation. Human 
monocyte/macrophages from a single donor were cultured from 1 to 
12 days. Intracellular NAD concentration was determined on the cell 
homogenate. Cellular NAD concentration increased significantly with time 
corresponding with the stage of cell differentiation from monocyte to 
macrophage. *P < .01; **P < .05 (n = 3-8).
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concentration was lower in activated macrophage cultures in 
the presence of 3ABA, this did not reach statistical signifi-
cance (Figure 7).
Discussion
Various KP metabolites have been detected in the extracellular 
fluid of immune-activated cells.13,14 However, the relationship 
between increased oxidative tryptophan catabolism and de 
novo NAD synthesis has not been investigated.
Although previous studies using a macrophage cell line15 
strongly suggest an increase in NAD synthesis and catabolism 
following IDO induction by IFN-γ, a repeat of these studies 
was needed in nontransformed primary cells.
The effect of IFN-γ on IDO induction and intracellular 
NAD concentration was investigated in human 
monocyte-derived macrophages (MDM) at 3 stages of 
differentiation:
1. Undifferentiated (fresh monocytes);
2. Partially differentiated (after day 6 in culture);
3. Fully differentiated (day 10 in culture) MDMs.
Monocyte to macrophage differentiation
Mononuclear phagocytes play an important role in host cell–
mediated immunity. Undifferentiated monocytes are released 
continually into the bloodstream from the bone marrow. These 
cells then migrate to the viscera where local factors initiate the 
process of differentiation into specialised resident macrophages. 
During inflammation, the release of chemotactic cytokines 
increases the migration of monocytes to the site of injury. These 
infiltrating monocytes along with the resident macrophages are 
then activated by soluble factors, in particular, IFN-γ.16
In this study, it was found that KP metabolism was increased 
to a much greater extent in differentiated compared with 
undifferentiated cells in response to IFN-γ, as determined by 
IDO activity, kynurenine, QUIN, and NAD assays.
IDO induction by IFN-γ in MDMs
Consistent with previous reports, IFN-γ effectively increased 
IDO activity in these cultured monocyte/macrophages14 at all 
stages of differentiation in a dose-dependent fashion (Figures 2 
and 3).
In this study, we found that, in agreement with previous 
investigations,17 exposure to the same concentration of IFN-γ 
produced a much greater increase in IDO activity in differenti-
ated macrophages compared with undifferentiated monocytes 
(Figure 2 & 3). This is consistent with an overall greater meta-
bolic activity and response to immune modulators in mac-
rophages compared with monocytes.
Figure 5. Effect of IFN-γ and 3ABA on intracellular NAD concentration in 
monocytes (A): 6-day-old MDM and 10-day-old MDM. Human MDMs 
from 4 different donors were cultured for the times indicated and then 
either left untreated (C) or treated with IFN-γ (600 U/mL) and/or 3ABA 
(≥5 mM) for 24 or 48 hours. NAD concentration was determined on the 
cell homogenate. (A) *P < .01; **P < .05; ***P < .001 (n = 3-23). (B) *P < .001; 
**P < .05 (n = 3-10). (C) *P < .05; **P < .01 (n = 8-19). Statistics used was the 
Tukey-Kramer analysis of variance. 3ABA indicates 3-aminobenzamide; 
MDMs, monocyte-derived macrophages.
Figure 6. Effect of IFN-γ on quinolinic acid production in human 
monocyte/macrophages. Human monocyte/macrophage cells from 3 
different donors were cultured for either 0 or 10 days and then either left 
untreated (C) or treated with IFN-γ (600 U/mL) for 48 hours. Quinolinic 
acid concentration was determined in the culture supernatant. *P < .0001 
compared with (C) day 0; **P < .0001 compared with (C) day 10; 
***P < .0001 compared with IFN-γ day 0 (n = 4-7).
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Effect of IFN-γ activation at different stages of cell 
differentiation on QUIN production
Consistent with the pattern shown for IDO activity 
(Figures 2 and 3), QUIN production was much greater in 
IFN-γ–activated macrophages compared with monocytes 
(Figure 6).
This demonstrates an increased flux through this pathway 
at least as far as QUIN under these conditions.
Quinolinic acid concentration in the extracellular fluid, how-
ever, was approximately an order of magnitude lower than that 
for kynurenine (Figure 7B and C), indicating that only a 
relatively small percentage of degraded tryptophan is secreted as 
QUIN under these conditions. The reason for this is not clear. 
Kynurenine can be converted to at least 2 other metabolites 
besides 3-hydroxykynurenine, kynurenic acid, and anthranilic 
acid. Although MDMs do not appear to secrete kynurenic 
acid15 unless stimulated by TLR-3,18 the kynurenine excreted 
by these cells may be taken up by other cells within the vicinity 
of the inflammation site and used for either de novo production 
of NAD or synthesis of either/or both of these 2 alternative 
compounds.
Interestingly, the mild inhibitory effect of 3ABA on IDO 
did not significantly affect the level of QUIN secretion indicat-
ing that kynurenine production at maximum activation may be 
saturating downstream enzymes with substrate.
A more extensive investigation using coculture techniques is 
needed to provide further insight into the fate of kynurenine 
under these conditions.
Effect of IFN-γ activation, in the presence 
or absence of 3ABA, at different stages of cell 
differentiation on intracellular NAD concentration
The intracellular NAD concentration in unactivated cells 
increased with the amount of time spent in culture. This cor-
responded to the level of cell differentiation from monocyte 
(lowest NAD content) to macrophage (highest NAD content) 
(Figure 4).
This is consistent with the increase in morphological size, 
and we assume metabolic requirements, of the cell in direct 
relation to the degree of differentiation.
Following 24-hour treatment with 3ABA (PARP inhibi-
tion), intracellular NAD increased in unactivated cells at days 6 
and 10 but not day 0 (Figure 5A to C), suggesting that NAD 
catabolism due to PARP activity increases as a consequence of 
in vitro cell differentiation.
It has been known for some time that activation of human 
MDM with IFN-γ also increases PARP activity.19 Following 
IFN-γ activation, intracellular NAD concentration decreased 
significantly in cells at all 3 stages of differentiation (Figure 5A 
to C), indicating that the catabolism of NAD in these activated 
cells was greater than its synthesis.
NAD levels, however, in these IFN-γ–activated cells in the 
presence of the PARP inhibitor, 3ABA, was either retained 
(Figure 5A) or significantly increased (Figure 5B and C). 
Increased de novo synthesis of NAD in undifferentiated cells 
(day 0) is not expected as induction of IDO by IFN-γ in 
monocytes is negligible at 24 hours (Figure 2). The significant 
increase in NAD levels after activation and PARP inhibition 
on days 6 and 10 (Figure 5B and C), however, appears to 
reflect the corresponding significant increase in IDO activity 
(Figure 3).
Although 24-hour exposure to IFN-γ in the presence of a 
PARP inhibitor resulted in a significant increase in cellular 
Figure 7. The effect of 3ABA on kynurenine pathway metabolism: 
10-day-old macrophages were either left untreated or treated with 3ABA 
or IFN-γ or 3ABA + IFN-γ. After 48 hours, samples were taken and 
analysed for (A) IDO activity, determined from the cell homogenate. 
Results are presented as a percentage of untreated control cultures (C), 
*P < .005 (n = 5-6) compared with IFN-γ. (B) Kynurenine concentration in 
the culture supernatant, *P < .05 (n = 5-6) compared with IFN-γ. (C) 
Quinolinic acid concentration in the culture supernatant, *P < .001 (n = 5-6) 
compared with control (C). 3ABA indicates 3-aminobenzamide; IDO, 
indoleamine 2,3-dioxygenase.
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NAD coinciding with increased IDO activity, 48-hour expo-
sure to IFN-γ and 3ABA did not reproduce this result (Figure 
5A and C). The reasons for this are not clear. Figure 7 shows 
that treatment with 3ABA for 48 hours reduces both IDO 
activity and supernatant kynurenine concentration in IFN-γ–
activated cells, whereas QUIN levels were marginally reduced 
in 3ABA-treated unactivated cells only. This suggests that 
exposure to 3ABA for longer periods may reduce flux through 
the KP to some degree. However, as the production of the 
immediate NAD precursor QUIN was not significantly 
reduced, NAD synthesis may not be affected. It is possible, 
though, that longer term activation of these cells (ie, 48 hours) 
may result in either an accumulation of cytotoxic products in 
the static culture medium or a decrease in essential metabolic 
cofactors, both of which may affect enzyme involved in the 
synthesis of NAD.
Conversion of QUIN into NAD requires cofactors, such as 
phosphoribosyl pyrophosphate, adenosine triphosphate, and 
glutamine, any of which may become depleted over time and 
thereby rate limiting in the synthesis of NAD. Further studies 
are required to test this hypothesis. In addition, it has been sug-
gested by others that expression of the NAD synthetic enzyme 
quinolinate phosphoribosyl transferase in macrophages may be 
dependent on specific stimulatory signals20 which may be dis-
rupted in the presence of 3ABA.
Conclusions
In conclusion, this study using human MDMs has provided 
evidence which indicates that an immune-mediated increase in 
IDO activity does increase NAD biosynthesis concomitantly 
with an increase in NAD catabolism. This phenomenon was 
clearly observed in differentiated cells after 24-hour exposure 
to maximal activating doses of IFN-γ but was less obvious after 
48 hours.
These results are consistent with data from a previous study 
using the RAW264.7 monocyte/macrophage cell line.15 
However, the process of NAD synthesis in the human primary 
cells following IDO induction by IFN-γ appears to be affected 
by the degree of cell differentiation at the time of immune 
activation.
These results do support a role for IDO induction in 
increased NAD synthesis which may provide substrate for con-
tinuing PARP activity facilitating nuclear repair and hence 
long-term cell (ie, monocyte/macrophage) viability. As inhibi-
tors for IDO have been developed for potential clinical use in 
inflammatory-associated conditions,21 recognition of the role 
of IDO induction and its role in maintaining NAD+ levels in 
front-line immune cells may be relevant to developing final 
effective treatment regimens.
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